Literature DB >> 24626958

Pathobiology of cervical spondylotic myelopathy.

Spyridon K Karadimas1, Georgios Gatzounis, Michael G Fehlings.   

Abstract

In this narrative review, we aim to outline what is currently known about the pathophysiology of cervical spondylotic myelopathy (CSM), the most common cause of spinal cord dysfunction. In particular, we note the unique factors that distinguish it from acute spinal cord injury. Despite its common occurrence, the reasons why some patients develop severe symptomatology while others have few or no symptoms despite radiographic evidence confirming similar degrees of compression is poorly understood. Neither is there a clear understanding of why certain patients have a stable clinical myelopathy and others present with only mild myelopathy. Moreover, the precise molecular mechanisms which contribute to the pathogenesis of the disease are incompletely understood. The current treatment method is decompression of the spinal cord but a lack of clinically relevant models of CSM have hindered the understanding of the full pathophysiology which would aid the development of new therapeutic avenues of investigation. Further elucidation of the role of ischemia, currently a source of debate, as well as the complex cascade of biomolecular events as a result of the unique pathophysiology in this disease will pave the way for further neuroprotective strategies to be developed to attenuate the physiological consequences of surgical decompression and augment its benefits.

Entities:  

Mesh:

Year:  2014        PMID: 24626958     DOI: 10.1007/s00586-014-3264-4

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  42 in total

1.  Viscoelastic relaxation and regional blood flow response to spinal cord compression and decompression.

Authors:  G D Carlson; K E Warden; J M Barbeau; E Bahniuk; K L Kutina-Nelson; C L Biro; H H Bohlman; J C LaManna
Journal:  Spine (Phila Pa 1976)       Date:  1997-06-15       Impact factor: 3.468

2.  Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy.

Authors:  Wen Ru Yu; Tianyi Liu; Tim-Rasmus Kiehl; Michael G Fehlings
Journal:  Brain       Date:  2011-04-13       Impact factor: 13.501

Review 3.  Morphofunctional aspects of the blood-brain barrier.

Authors:  Beatrice Nico; Domenico Ribatti
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

4.  Immunohistochemical profile of NF-κB/p50, NF-κB/p65, MMP-9, MMP-2, and u-PA in experimental cervical spondylotic myelopathy.

Authors:  Spyridon K Karadimas; George Klironomos; Dionysios J Papachristou; Sofia Papanikolaou; Eleni Papadaki; George Gatzounis
Journal:  Spine (Phila Pa 1976)       Date:  2013-01-01       Impact factor: 3.468

Review 5.  Cervical spondylosis. An update.

Authors:  B M McCormack; P R Weinstein
Journal:  West J Med       Date:  1996 Jul-Aug

Review 6.  Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder.

Authors:  Sukhvinder Kalsi-Ryan; Spyridon K Karadimas; Michael G Fehlings
Journal:  Neuroscientist       Date:  2012-11-30       Impact factor: 7.519

Review 7.  Pathophysiology and natural history of cervical spondylotic myelopathy.

Authors:  Spyridon K Karadimas; W Mark Erwin; Claire G Ely; Joseph R Dettori; Michael G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-15       Impact factor: 3.468

Review 8.  A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury.

Authors:  M G Fehlings; G Skaf
Journal:  Spine (Phila Pa 1976)       Date:  1998-12-15       Impact factor: 3.468

9.  Experimental chronic compressive cervical myelopathy.

Authors:  O al-Mefty; H L Harkey; I Marawi; D E Haines; D F Peeler; H I Wilner; R R Smith; H R Holaday; J L Haining; W F Russell
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

10.  A novel experimental model of cervical spondylotic myelopathy (CSM) to facilitate translational research.

Authors:  Spyridon K Karadimas; Eun Su Moon; Wen-Ru Yu; Kajana Satkunendrarajah; Joannis K Kallitsis; Georgios Gatzounis; Michael G Fehlings
Journal:  Neurobiol Dis       Date:  2013-03-04       Impact factor: 5.996

View more
  54 in total

1.  The Michel Benoist and Robert Mulholland yearly European spine journal review: a survey of the "surgical and research" articles in the European spine journal, 2015.

Authors:  Robert C Mulholland
Journal:  Eur Spine J       Date:  2016-01-05       Impact factor: 3.134

Review 2.  [Spondylotic cervical myelopathy : Indication of surgical treatment].

Authors:  W Pepke; H Almansour; M Richter; M Akbar
Journal:  Orthopade       Date:  2018-06       Impact factor: 1.087

3.  Cervical arteriosclerosis is associated with preoperative clinical symptoms in patients with cervical spondylotic myelopathy.

Authors:  Gentaro Kumagai; Kanichiro Wada; Sunao Tanaka; Toru Asari; Yasuyuki Ishibashi
Journal:  Eur Spine J       Date:  2020-11-09       Impact factor: 3.134

4.  Differences in clinical and radiological features of thoracic disc herniation presenting with acute progressive myelopathy.

Authors:  Hideaki Nakajima; Shuji Watanabe; Kazuya Honjoh; Arisa Kubota; Akihiko Matsumine
Journal:  Eur Spine J       Date:  2020-06-07       Impact factor: 3.134

5.  Association of VDR-FokI and VDBP-Thr420Lys polymorphisms with cervical spondylotic myelopathy: A case-control study in the population of China.

Authors:  De-Wei Song; Yu-Dong Wu; Dong-Dong Tian
Journal:  J Clin Lab Anal       Date:  2018-11-21       Impact factor: 2.352

6.  Magnetic Resonance Imaging Biomarker of Axon Loss Reflects Cervical Spondylotic Myelopathy Severity.

Authors:  Rory K J Murphy; Peng Sun; Junqian Xu; Yong Wang; Samir Sullivan; Paul Gamble; Joanne Wagner; Neill N Wright; Ian G Dorward; Daniel Riew; Paul Santiago; Michael P Kelly; Kathryn Trinkaus; Wilson Z Ray; Sheng-Kwei Song
Journal:  Spine (Phila Pa 1976)       Date:  2016-05       Impact factor: 3.468

7.  Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial.

Authors:  S Rajasekaran; Siddharth N Aiyer; Ajoy Prasad Shetty; Rishi Mugesh Kanna; Anupama Maheswaran; Janardhan Yerram Shetty
Journal:  Eur Spine J       Date:  2015-11-23       Impact factor: 3.134

8.  Fractional anisotropy to quantify cervical spondylotic myelopathy severity.

Authors:  Rory K Murphy; Peng Sun; Rowland H Han; Kim J Griffin; Joanne Wagner; Chester K Yarbrough; Neill M Wright; Ian G Dorward; K Daniel Riew; Michael P Kelly; Paul Santiago; Lukas P Zebala; Kathryn Trinkaus; Wilson Z Ray; Sheng-Kwei Song
Journal:  J Neurosurg Sci       Date:  2016-05-05       Impact factor: 2.279

Review 9.  Degenerative cervical myelopathy - update and future directions.

Authors:  Jetan H Badhiwala; Christopher S Ahuja; Muhammad A Akbar; Christopher D Witiw; Farshad Nassiri; Julio C Furlan; Armin Curt; Jefferson R Wilson; Michael G Fehlings
Journal:  Nat Rev Neurol       Date:  2020-01-23       Impact factor: 42.937

10.  The Restless Spinal Cord in Degenerative Cervical Myelopathy.

Authors:  M Hupp; N Pfender; K Vallotton; J Rosner; S Friedl; C M Zipser; R Sutter; M Klarhöfer; J M Spirig; M Betz; M Schubert; P Freund; M Farshad; A Curt
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.